FIELD: medicine.
SUBSTANCE: present group of inventions relates to medicine, specifically to therapy and endocrinology, and concerns application of an agent with modifying properties in relation to adrenal hormones. Method includes administering an effective amount of compound of formula I or a pharmaceutically acceptable salt thereof. For compound of formula I n equals 1; R is hydrogen, R1, R2 and R3 independently represent hydrogen, halogen or cyano group, provided that not more than one from R1, R2 and R3 denotes hydrogen, and R4 and R5 represent hydrogen.
.
EFFECT: efficient treatment of diseases and disorders, characterised by high level of stress hormones.
24 cl, 2 dwg, 2 tbl, 8 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMBINATION OF SOMATOSTATIN ANALOGUES WITH 11β-HYDROXYLASE INHIBITORS | 2013 |
|
RU2663455C2 |
| METHOD OF PRODUCING CONDENSED IMIDAZOLE DERIVATIVES | 2016 |
|
RU2734818C2 |
| HUMAN CYTOCHROME 11B2 INHIBITORS | 2022 |
|
RU2789610C1 |
| HUMAN ALDOSTERONE SYNTHASE (CYP11B2) INHIBITORS | 2023 |
|
RU2824362C1 |
| NOVEL COMPOUNDS 3,4-DIHYDRO-2N-ISOQUINOLIN-1-ONE AND 2,3-DIHYDROISOINDOL-1-ONE | 2014 |
|
RU2693698C2 |
| HUMAN CYTOCHROME 11B2 INHIBITORS | 2022 |
|
RU2800378C1 |
| 3,4-DIHYDRO-2H-ISOQUINOLINE-1-ONE AND 2,3-DIHYDRO-ISOINDOL-1-ONE DERIVATIVES USEFUL AS ALDOSTERONE SYNTHASE INHIBITOR | 2014 |
|
RU2695524C2 |
| NOVEL 3,4-DIHYDRO-2H-ISOQUINOLIN-1-ONES AND 2,3-DIHYDRO-ISOINDOLE-1-ONES | 2014 |
|
RU2689421C2 |
| HUMAN CYTOCHROME 11B2 INHIBITORS | 2021 |
|
RU2783521C1 |
| CFR RECEPTOR ANTAGONISTS FOR TREATMENT OF CONGENITAL ADRENAL HYPERPLASIA | 2015 |
|
RU2812318C2 |
